News
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
21h
Everyday Health on MSNZebound Beats Wegovy for Weight Loss in First Head-to-Head TrialIn a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...
22hon MSN
“I’m down about 50 pounds. I want to lose another 50,” Barkley said, revealing he gained 100 pounds after hip surgery. The target weight, he said, is 270 pounds. He said he is taking Zepbound, a ...
22hon MSN
Shapiro, a Democrat who is considered a potential White House contender in 2028, said that if the cuts are made, the state would be unable to make up that amount of lost federal aid.
6h
Barchart on MSNThis Pharma Stock Is Still a ‘Strong Buy’ Despite Trump’s Plans to Lower Drug PricesWhile the early week buzz centered around the U.S.-China trade agreement, another critical development unfolded quietly but ...
While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...
5h
Zacks Investment Research on MSNSepterna Stock Surges on Oral Obesity Drug Deal With Novo NordiskShares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...
Less than 3% of all people in the U.S. who are eligible for injectable weight loss drugs get a prescription for it, a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results